gimli
NOVARTIND stock analysis context
NOVARTIS INDIA Stock Context for AI Screening
NOVARTIS INDIA LIMITED is a small-cap stock in Healthcare. This page summarizes key screening signals for NOVARTIS INDIA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Open interactive NOVARTIND stock pagePrice
₹1,323.10
1W return
-6.54%
1M return
+28.39%
3M return
n/a
6M return
n/a
1Y return
n/a
Market cap
₹3,266.84 cr
PE
47.37
PB
3.99
ROE
n/a
ROCE
n/a
RSI
54.95
Turnover
₹7.12 cr
Why it can matter in screens
- Momentum: NOVARTIND is trend mixed or unavailable; RSI is 54.95.
- Returns: 1D -9.72%, 1W -6.54%, 1M +28.39%, 3M n/a, 1Y n/a.
- Trend levels: 52W high ₹1,556.60, 52W low ₹962.00, off high -15.00%.
- Liquidity: latest turnover is ₹7.12 cr; volume vs 20D is +1.02%.
- Valuation/profitability: PE 47.37, PB 3.99, ROE n/a, ROCE n/a.
- Growth: 3Y sales CAGR n/a, 3Y profit CAGR n/a.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 90.55 cr | 30.63 cr | 25.25 cr | 10.23 |
| 2025-12-31 | 85.90 cr | 31.11 cr | 16.09 cr | 6.52 |
| 2025-09-30 | n/a | n/a | n/a | 9.81 |
| 2025-06-30 | 87.55 cr | 37.85 cr | 27.62 cr | 11.19 |
| 2025-03-31 | 83.88 cr | 34.54 cr | 29.30 cr | 11.87 |
| 2024-12-31 | 93.00 cr | 36.18 cr | 25.45 cr | nan |
| 2024-09-30 | 87.10 cr | 28.28 cr | 20.41 cr | 8.27 |
Annual income statement
No recent data available.
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 978.27 cr | 52.50 cr | 3.21 cr | 817.83 cr |
| 2025-03-31 | 947.81 cr | 52.07 cr | 5.06 cr | 784.96 cr |
| 2024-09-30 | 890.91 cr | 21.07 cr | 6.03 cr | 729.24 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | n/a | n/a | n/a |
| 2025-12-31 | n/a | n/a | n/a |
| 2025-09-30 | n/a | n/a | n/a |
| 2025-06-30 | n/a | n/a | n/a |
| 2025-03-31 | n/a | n/a | n/a |
Shareholding Trend
No recent data available.
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 429,121.06 cr | 40.824543 | +15.06% | +7.26% |
| DIVISLAB | DIVI S LABORATORIES LTD | 174,585.42 cr | 68.707369 | +17.81% | +0.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 147,849.87 cr | 68.354079 | +29.94% | +39.35% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 119,204.71 cr | 64.295958 | +23.21% | +21.70% |
| CIPLA | CIPLA LTD | 111,088.72 cr | 29.624450 | +12.91% | -6.65% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 108,331.15 cr | 21.874917 | +20.44% | +16.21% |
| DRREDDY | DR. REDDY S LABORATORIES | 105,181.70 cr | 24.542479 | +13.88% | +1.20% |
| LUPIN | LUPIN LIMITED | 103,385.66 cr | 22.341869 | +29.22% | +15.72% |
Try these prompts
- Analyze NOVARTIS INDIA with valuation, momentum and industry peers
- Compare NOVARTIND with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare NOVARTIND with other Healthcare stocks
Data snapshot: 2026-06-03. Not investment advice.